Table 3.
Patient | Sepsis based on qSOFA ≥ 2 | Sepsis based on clinically suspected systemic infection | Sepsis based on qSOFA ≥ 2 and clinically suspected systemic infection | Fever | Organisms isolated | Sensitive to | Intermediate sensitivity | Resistant to |
---|---|---|---|---|---|---|---|---|
A | Yes | Yes | Yes | Yes | Proteus mirabilis | Imipenem | – | Amoxicillin–clavulanic acid, ampicillin, cefotaxime, ceftriaxone, chloramphenicol, ciprofloxacin, gentamicin, nalidixic acid, and trimethoprim–sulfamethoxazole |
B | Yes | Yes | Yes | Yes | Klebsiella oxytoca | Chloramphenicol, ciprofloxacin, and nalidixic acid | – | Amoxicillin–clavulanic acid, ampicillin, cefotaxime, ceftriaxone, gentamicin, and trimethoprim–sulfamethoxazole |
Escherichia coli | Gentamicin | Chloramphenicol, ciprofloxacin, and nalidixic acid | Amoxicillin–clavulanic acid, ampicillin, cefotaxime, ceftriaxone, and trimethoprim–sulfamethoxazole | |||||
C | No | Yes | No | No | Coagulase-negative Staphylococcus | Ciprofloxacin and cefoxitin | – | Cefoxitin, gentamicin, and oxacillin |
D | No | Yes | No | Yes | Candida glabrata | NR* | NR* | NR* |
qSOFA = quick sequential organ failure.
Sensitivities for Candida were not reported by laboratory.
Mycobacterial cultures were negative for all patients.
Blood cultures were missing for five (7%) subjects, and urine cultures were missing for 21 (28%) subjects.